Observational studyInternational journal of dermatology2026
CH50 as a Clinically Useful Biomarker of Disease Activity and Antihistamine Resistance in Chronic Spontaneous Urticaria: An Observational Ambispective Single-Center Study.
Observational study in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic spontaneous urticaria (CSU) is frequently refractory to guideline-based therapy, highlighting the need for predictive biomarkers. Dysregulation of the complement system has been implicated in CSU severity, but global complement activity has not been systematically evaluated.
objectiveThe aim of this study was to assess the total hemolytic complement (CH50) assay as a biomarker for disease activity and predictor of treatment response in CSU.
methodsThis observational, ambispective, single-center study included 180 CSU patients and 45 healthy controls. CH50 levels were measured and correlated with clinical and immunological markers. Response to second-generation antihistamines and omalizumab at 3, 6, and 12 months was evaluated.
resultsCH50 levels were significantly higher in CSU patients than in controls (p < 0.001) and were associated with more active and prolonged disease. CH50 correlated with Weekly Urticaria Activity Scores (UAS7) (ρ = 0.30, p < 0.0001), Urticaria Control Test (UCT) scores (ρ = -0.25, p < 0.001), longer disease duration (ρ = 0.28, p = 0.0002), D-dimer (ρ = 0.31, p < 0.001), and immunoglobulin G (IgG) anti-thyroid peroxidase (anti-TPO) (ρ = 0.21, p < 0.005). Higher CH50 levels were linked to antihistamine resistance (p < 0.001), with superior predictive accuracy (area under the curve [AUC] = 0.87) over D-dimer, C4, and UAS7. CH50 was also an independent predictor of antihistamine resistance (odds ratio [OR] 1.13, 95% confidence interval [CI] 1.09-1.18). No association was observed with omalizumab response.
conclusionCH50 is a novel and promising biomarker for antihistamine resistance in CSU, outperforming previously described markers. Its low cost and accessibility support integration into CSU stratification and endotype-driven therapeutic algorithms, pending validation in multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.